Amerise Biosciences Ltd (531681)
Latest quarterly results (Q4 FY26)
In its latest reported quarter, Q4 FY26, Amerise Biosciences' revenue was ₹0.1 Cr (-57.9% year on year, +100.0% on the previous quarter), and net profit ₹0.1 Cr (-45.5% year on year); the operating margin was 75.0%.
| Q4 FY26 (₹ Cr) | Value | YoY vs Q4 FY25 | QoQ |
|---|---|---|---|
| Revenue | ₹0.1 | -57.9% | +100.0% |
| Operating profit | ₹0.1 | -45.5% | +500.0% |
| Net profit | ₹0.1 | -45.5% | +500.0% |
| EPS (₹) | 0.01 | -50.0% | — |
| Operating margin | 75.0% | — | — |
📢 Recent Corporate Announcements
Amerise Biosciences reported zero revenue from operations for the quarter ended June 30, 2026, a sharp decline from Rs 7.92 lakhs in the previous quarter. The company swung to a net loss of Rs 8.14 lakhs, compared to a profit of Rs 6.13 lakhs in the March 2026 quarter. Total expenses for the period stood at Rs 8.14 lakhs, primarily driven by 'Other expenses' of Rs 7.21 lakhs. The company's paid-up equity capital remains unchanged at Rs 660.69 lakhs.
- Revenue from operations dropped to Rs 0.00 in Q1 FY27 from Rs 7.92 lakhs in Q4 FY26.
- Net loss for the quarter was Rs 8.14 lakhs compared to a profit of Rs 6.13 lakhs in the preceding quarter.
- Other expenses accounted for 88.5% of total quarterly expenditure at Rs 7.21 lakhs.
- Employee benefit expenses decreased to Rs 0.94 lakhs from Rs 1.45 lakhs in the previous quarter.
- Basic and Diluted EPS turned negative at Rs (0.01) for the quarter.
Amerise Biosciences Ltd reported a complete halt in revenue for the quarter ended June 30, 2026, recording Rs 0.00 in operations compared to Rs 7.92 lacs in the previous quarter. The company posted a net loss of Rs 8.14 lacs, a sharp reversal from the Rs 6.13 lacs profit recorded in Q4 FY26. Expenses were dominated by 'Other Expenses' at Rs 7.21 lacs, while employee benefit expenses stood at Rs 0.94 lacs. The company continues to operate with negative 'Other Equity' of Rs 121.10 lacs as of March 2026, indicating sustained financial pressure.
- Revenue from operations dropped to Rs 0.00 in Q1 FY27 from Rs 7.92 lacs in Q4 FY26.
- Net loss for the quarter was Rs 8.14 lacs compared to a profit of Rs 6.13 lacs in the preceding quarter.
- Other expenses accounted for 88.5% of total quarterly expenditure at Rs 7.21 lacs.
- Paid-up equity share capital remains at Rs 660.69 lacs with a face value of Rs 1 per share.
- Other Equity remains negative at Rs -121.10 lacs as per the last audited balance sheet.
Amerise Biosciences reported a net loss of Rs 8.14 Lakhs for the quarter ended June 30, 2026, a significant decline from a profit of Rs 6.13 Lakhs in the previous quarter (Q4 FY26). Revenue from operations fell to zero during the quarter, compared to Rs 7.92 Lakhs in the sequential quarter and Rs 6.37 Lakhs in the year-ago period. Total expenses for the quarter were Rs 8.14 Lakhs, primarily driven by 'Other expenses' of Rs 7.21 Lakhs. The company continues to operate at an extremely small scale with a total paid-up equity capital of Rs 6.61 Cr.
- Revenue from operations dropped to Rs 0.00 in Q1 FY27 from Rs 7.92 Lakhs in Q4 FY26.
- Net loss for the quarter stood at Rs 8.14 Lakhs compared to a profit of Rs 6.13 Lakhs in the preceding quarter.
- Other expenses accounted for the majority of the quarterly spend at Rs 7.21 Lakhs.
- Employee benefit expenses were recorded at Rs 0.94 Lakhs for the quarter.
- Paid-up equity share capital remains unchanged at Rs 660.69 Lakhs (Face Value Rs 1).
Amerise Biosciences has received a disclosure under Regulation 29(2) of SEBI (SAST) Regulations from Snehjeev Ventures Pvt Ltd and Persons Acting in Concert (PACs). This regulation requires disclosure when a shareholder's stake changes by more than 2%. Given the company's extremely small scale, with FY26 revenue of only ₹0.26 Cr and a net worth of ₹5 Cr, any movement by significant investors is notable. However, the specific volume and direction of the trade (buy or sell) were not detailed in this specific cover letter.
- Disclosure filed under Regulation 29(2) of SEBI (SAST) Regulations, 2011
- Involves Snehjeev Ventures Pvt Ltd and PACs as the reporting entities
- Filing received and acknowledged by the company on July 29, 2026
- Company operates on a micro-scale with FY26 revenue of just ₹0.26 Cr
- Stock is currently trading at a penny-stock level of ₹0.9
Amerise Biosciences has scheduled a board meeting for August 3, 2026, to consider and approve the un-audited financial results for the quarter ended June 30, 2026. The company is a micro-cap entity with a very small financial footprint, reporting a total revenue of just ₹0.19 crore for the full year FY25. While the March 2026 quarter showed a slight uptick in revenue to ₹0.08 crore and a profit of ₹0.06 crore, the overall scale remains extremely low. This meeting is a routine regulatory requirement for listed companies.
- Board meeting scheduled for August 3, 2026, to review Q1 FY27 results
- Company reported a marginal net profit of ₹0.06 crore in the preceding quarter (March 2026)
- Total annual revenue for FY25 was only ₹0.19 crore
- Net worth of the company stands at ₹5 crore as per latest available data
- Stock is currently trading at a low absolute price of ₹0.9
Financial Performance
Financial analysis data not yet available for this company.
Operational Drivers
Operational analysis data not yet available for this company.
Strategic Growth
Strategic growth analysis not yet available for this company.
External Factors
External factors analysis not yet available for this company.
Regulatory & Governance
Regulatory analysis not yet available for this company.
Risk Analysis
Risk analysis not yet available for this company.
